Drug intelligence / Profile preview

ivIGMA

Development stage: Discontinued
Administration: Intravenous

Overview

ivIGMA is an intravenous immunoglobulin preparation enriched with IgMA, IgA, and IgG, containing 7.8 g IgM, 7.8 g IgA, and 49.4 g IgG. It was investigated as a therapy for neutropenic patients suffering from hematologic malignancies and sepsis syndrome or septic shock. Clinical trials, however, indicated that ivIGMA therapy did not provide a beneficial effect on mortality compared to human albumin in this patient population.

Beyond the preview

Go deeper on ivIGMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivIGMA.

Explore the full profile